Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
COVID-19 Therapeutic Development
With Synthetic Antibody Technology
Sachdev Sidhu
Toronto Recombinant Antibody Centre
The Donnelly Centre
University of Toronto
https://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2020/september/present/2b-2-sidhu-508.pdf
Ultrafine Particles Cross Cellular Membranes by Nonphagocytic...
... Hofer U, Lehmann A, Waelti E, Amacker M, Gehr P and Rothen-Rutishauser B (2009) Virosomes can enter cells by non-phagocytic mechanisms, Journal of Liposome Research, 10.3109/...
Size: 1.0MB
Date Modified: 06/26/2021
https://ehp.niehs.nih.gov/doi/10.1289/ehp.8006
Table of Contents page: Journal of Biological Chemistry
www.jbc.org › issue › S0021-9258(19)X7094-5
Feb 07, 1997 · Toon Stegmann; Published in issue: February 07, 1997 ... Binding of Mammalian Ribosomal Protein Complex P0·P1·P2 and Protein L12 to the GTPase-associated Domain of ..
https://www.jbc.org/action/doSearch?text1=+Ribosomal&field1=AllField
Volker Thiel, COVID-19 Virtual Symposium: May 27, 2020
Castaways
I deleted my post, Because I could not find the proof. I know it was in a post some where with WH,SP1, Etc. But can not find, My Apologies!!! I will look more into it!!
WHO says fully vaccinated people should continue to wear masks because of Delta variant spread
Connor Perrett Jun 26, 2021, 7:16 AM
"People cannot feel safe just because they had the two doses," a WHO official said.
The statement comes amid concerns over the quickly spreading Delta variant of COVID-19.
https://www.businessinsider.com/delta-variant-who-fully-vaccinated-wear-masks-2021-6
Now is the time Mr. Kemper's to act on what you got/ Release to the public
that way someone should help to fund it. GET BUSY!!!
Characterization of the fusogenic properties of Sendai virus ...
pubs.acs.org › doi › 10
Acidic pH Enhancement of the Fusion of Newcastle Disease Virus with Cultured Cells. ... Shlomo Nir, Toon Stegmann, Dick Hoekstra, Jan Wilschut.
Author: Dick Hoekstra, Katharina Klappe, T Deboer, Jan Wilschut
Cited by: 116
https://pubs.acs.org/doi/abs/10.1021/bi00339a005
Inactivation of PR8 influenza virus through the ...
pubs.acs.org › doi › 10
Jan 26, 1993 · Acidic pH Enhancement of the Fusion of Newcastle Disease Virus with Cultured Cells. ... Romke Bron, Antonio Ortiz, Jan Dijkstra, Toon Stegmann, Jan Wilschut. [23 ...
Author: Heidi Wunderli-Allenspach, Maja Guenthert, Susanne Ott
Cited by: 21
https://pubs.acs.org/doi/10.1021/bi00054a022
Parameters Affecting the Fusion of Viruses with Artificial ...
rd.springer.com › chapter › 10
Paramyxoviruses, such as Sendai virus or Newcastle disease virus, but also measles viridae, fuse directly with the plasma membrane at neutral pH. Most other viruses, such as toga viruses (e.g. Semliki Forest Virus) and orthomyxoviruses (e.g. influenza viruses) are fusing with the endosomal membrane ‘from within’, after being internalized by .
Parameters Affecting the Fusion of Viruses with Artificial and Biological Membranes
Authors
Authors and affiliations
Dick Hoekstra Karin Klappe Toon Stegmann Shlomo Nir
https://rd.springer.com/chapter/10.1007/978-1-4613-1659-6_29
Oral Dispersible Vaccine Comprising Virosomes WONG; Yik Teng ...
uspto.report › patent › app
AMACKER; Mario › Patent 16/696752. Inventors uspto.report › ... Newcastle disease, enzootic pneumonia, feline leukemia, atrophic rhinitis, erysipelas, foot and .
https://www.nature.com/articles/s41541-020-0190-9
Method of Preparation of Virosome
Selection of virus for virosomes
Virosomes are reconstituted viral envelope that can be derived
from different virus. In?uenza virus envelope is most often usedto produce virosome but virosome can also be made from Sen
-dai virus, Epstein-burr virus, HIV, sindbis, semliki-forest virus,friend murine leukaemia virus, herpes simplex virus, Newcastle
disease virus
https://www.academia.edu/9992197/Nanotechnology_Based_Virosomal_Drug_Delivery_Systems
WHERE O' WHERE IS MR. KEMPERS WHY DID LEAVE US HERE ALL ALONE!! WE NEED A FANTASTIC PR FROM YOU!
https://video.search.yahoo.com/yhs/search;_ylt=AwrWpyYXS9dgtSAApQoPxQt.;_ylu=Y29sbwNncTEEcG9zAzEEdnRpZAMEc2VjA3Nj?p=where+o+where+are+you+tonight&type=frontier_pc_homerun_portal&hsimp=yhs-frontier1&hspart=frontier&ei=UTF-8&fr=yhs-frontier-frontier1#id=1&vid=803989c49f7c4ba7486f58261de37d3d&action=view
STALLERGENES GREER: ALUSTAL®, THE COMPANY’S SUBCUTANEOUS ALLERGEN IMMUNOTHERAPY TREATMENT (SCIT) NOW AVAILABLE
ABOUT ALUSTAL®
Alustal® is an aluminium-based suspension for subcutaneous injection launched in 1997.The aluminum adjuvant allows the slow release of antigen at the injection site to stimulate the immune response.
Alustal® is indicated for Type I allergies (Gell and Coombs classification) mainly involving rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate), of a seasonal or perennial nature, in children, adolescents and adults.
https://www.stallergenesgreer.com/stallergenes-greer-alustalr-companys-subcutaneous-allergen-immunotherapy-treatment-scit-now
Would be Much better if you used VIROSOMES!!!!!!!!!!!!!
A scientist says he's found 13 Wuhan coronavirus sequences that were deleted from a US database — and claims they're a 'goldmine' for research into the virus' origins
Grace Dean Jun 24, 2021, 6:16 AM
A researcher in Seattle claims he's discovered 13 partial coronavirus sequences from samples collected in Wuhan, China, that were deleted from a US database last year.
The discovery could mean scientists researching the origins of the pandemic have been working with incomplete data, he said.
Dr. Jesse Bloom, a researcher at the Fred Hutchinson Cancer Center in Seattle, said Tuesday that he had recovered the deleted files from Google Cloud, and had reconstructed partial sequences of 13 viruses. He said they came from samples taken at the early stages of pandemic in Wuhan, where scientists first discovered SARS-CoV-2, the novel coronavirus that causes COVID-19.
https://www.businessinsider.com/covid-origins-wuhan-china-sequences-jesse-bloom-deleted-sequences-coronavirus-2021-6
Continue from last Post
The secretome of induced pluripotent stem cells reduces lung ...
www.ncbi.nlm.nih.gov › pmc › articles
Nov 10, 2014 · The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor. Amiq Gazdhar,Iwona Grad,Luca Tamò,Mathias Gugger,Anis Feki,and Thomas Geiser. Amiq Gazdhar. Department of Pulmonary Medicine, University Hospital, Bern, Friburgstrasse, Bern, 3010 Switzerland.
Author: Amiq Ur Rahman Gazdhar, I Grad, Luca Tamò, Mathias Gugger, Anis Feki, Thomas Geiser
Cited by: 65
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrotic lung disease, resulting in respiratory insufficiency and reduced survival. Pulmonary fibrosis is a result of repeated alveolar epithelial microinjuries, followed by abnormal regeneration and repair processes in the lung. Recently, stem cells and their secretome have been investigated as a novel therapeutic approach in pulmonary fibrosis. We evaluated the potential of induced pluripotent stem cells (iPSC) conditioned media (iPSC-cm) to regenerate and repair the alveolar epithelium in vitro and improve bleomycin induced lung injury in vivo.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445988/
Stem Cell Differentiation is Regulated by Extracellular .
Dec 12, 2017 · Stem Cell Res Ther 8: 104, ... maturation phases of human pluripotent stem cellderived cardiomyocytes. ... Mario Amacker, Ren-Wang Peng,
Author: Lucas R. Smith, Sangkyun Cho, Denn…
Cited by: 99
Detection of promoter activity by flow cytometric analysis of ...
Jul 15, 2002 · Anne-Lyse Ducrest, Mario Amacker, ... INO80 promotes H2A.Z occupancy to
regulate cell fate transition in pluripotent stem cells . Advertisement. Advertisement.
Author: Anne-Lyse Ducrest, Mario Amacker, J…
Cited by: 65
Catalent to Acquire RheinCell Therapeutics
Strengthens path towards industrialization of induced pluripotent stem cell-based therapies.
06.25.21
https://www.contractpharma.com/contents/view_breaking-news/2021-06-25/catalent-to-acquire-rheincell-therapeutics/
Selkirk Pharma is a contract manufacturing organization in the pharmaceutical industry that manufactures sterile drug products. It was established just over a year ago at its current headquarters at 827 W. First, in downtown Spokane.
The manufacturing processes also will be fully automated through the use of a Skan isolator and the new Skanfog technology, Selkirk Pharma says.
Skan AG is a company based in Switzerland that manufactures cleanroom equipment for the global pharmaceutical industry. Skanfog is a type of machine specifically made for working in a germ-free environment to provide efficient decontamination and assurance of sterility.
https://advantagespokane.com/news/young-selkirk-pharma-envisions-big-facility-on-west-plains-drug-packager-files-plans-for-30-million-plant/
Aaron Wahl - Pharmaceutical Manufacturing Supervisor ...
www.linkedin.com › in › aaron-wahl-a69b2047
Basel Area, Switzerland. ... Pharmaceutical Manufacturing Supervisor at Jubilant HollisterStier Contract Manufacturing & Services.
Location: Spokane, Washington
Jubilant Pharma Limited / Jubilant HollisterStier
https://www.jublhs.com/media/press-release
Ocugen, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, announced that it has entered into an agreement with Jubilant HollisterStier of Spokane, Washington for manufacturing of vaccine candidate COVAXIN® for the US and Canadian markets.
“We are fully committed to bringing COVAXIN to the US and Canadian markets because it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants.” said J.P. Gabriel, Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN® to our new partner.”
https://www.worldpharmatoday.com/news/ocugen-secures-manufacturing-partnership-for-us-production-of-covid-19-vaccine-candidate-covaxin/
ChAd-SARS-CoV-2-S is licensed in India to Bharat Biotech as BBV154. In the United States and Europe, Precision Virologics, Inc., holds the license for the investigational vaccine.
https://www.niaid.nih.gov/news-events/covid-19-nasal-vaccine
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163257509
Priyamvada Jain - Associate Director - Jubilant Life Sciences ...
in.linkedin.com › in › priyamvada-jain-8013121b
World Intellectual Property Organization, Geneva, Switzerland Issued Apr 2009. See credential. Groups ... Perseus Patrawala. Perseus Patrawala
Location: Delhi, India
https://www.linkedin.com/in/priyamvada-jain-8013121b/?originalSubdomain=in
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Request for Technavio's latest reports on directly and indirectly impacted markets. Market estimates include pre- and post-COVID-19 impact on the Allergy Immunotherapies Market Download free sample report
The market is concentrated, and the degree of concentration will accelerate during the forecast period. Aimmune Therapeutics Inc., ALK-Abelló AS, Allergy Therapeutics Plc, ASIT Biotech SA, DBV Technologies SA, HAL Allergy BV, Jubilant Life Sciences Ltd., Laboratorios LETI SLU, Merck KGaA, and Stallergenes Greer Plc are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
https://www.businesswire.com/news/home/20200610005574/en/COVID-19-Impact-Recovery-Analysis--Allergy-Immunotherapies-Market
Jubilant
Spokane,
Washington, USA
US FDA, MHRA, Health Canada, PMDA Japan approved facility for Sterile Injectables, US FDA and Health Canada approved facility for Allergy Therapy products
https://www.jubilantpharma.com/about-us/business-enablers/manufacturing
Jubilant HollisterStier Signs Manufacturing Agreement with Eli Lilly for COVID-19 Therapeutic Bamlanivimab
Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through one of its subsidiaries, Jubilant HollisterStier LLC , has signed new contract with Eli Lilly for contract manufacturing of a treatment for COVID-19. The drug will be manufactured at the Spokane, Washington, USA facility of the Company.
https://www.worldpharmatoday.com/news/jubilant-hollisterstier-signs-manufacturing-agreement-with-eli-lilly-for-covid-19-therapeutic-bamlanivimab/
That has Billy Gates written all over it!!!!!
Where's the BIG BONANZA CORPUS!!
https://upload.wikimedia.org/wikipedia/en/thumb/f/f1/Bonanza_title_screen.jpg/250px-Bonanza_title_screen.jpg
Jubilant HollisterStier broadens its expansion plans in East Spokane
Pharmaceutical company to double capacity by 2024
Natasha Nellis June 17th, 2021
Plans include adding a new high-speed 400-vial-per-minute injectable fill line, with isolator technology and two 300-square-foot lyophilizers, or freeze dryers, which remove water to extend shelf life or make material more convenient for transport.
https://www.spokanejournal.com/local-news/jubilant-hollisterstier-broadens-its-expansion-plans-in-east-spokane/
https://www.spokesman.com/stories/2021/jun/15/jubilant-hollisterstier-in-spokane-to-add-200-jobs/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155135975
JUBILANT LIFE SCIENCES (SWITZERLAND) AG
www.jubilantpharmova.com › uploads › file
Jubilant Pharma Pte Ltd - The Holding Company 100,000 100% 100,000 100% Name of the shareholder No. of shares % held No. of shares % held Jubilant Pharma Pte Ltd - The Holding Company 100,000 100% 100,000 100%
https://www.jubilantpharmova.com/uploads/file/Jubilant_Life_Sciences_Switzerland_AG.pdf
Any CEO, Penny Stock can not be trusted at all. They all lie!!!!
Fruci Financial Services merges into Portland firm
Medical billing operation will retain its 86 employees, will remain in Spokane, WA. April 6th, 2001
Fruci Financial Services Inc., a Spokane-based medical management and billing company with 86 employees, has been merged into Portland-based Anesthesiologists Associated Inc. (AAI) and has assumed the AAI name.
https://www.spokanejournal.com/local-news/fruci-financial-services-merges-into-portland-firm/
Vaccines: The What, How, and Why with Maria Elena Bottazzi
Maria Elena Bottazzi is associate dean at the National School of Tropical Medicine at Baylor College of Medicine in Texas, and vaccine scientist who specializes in tropical, infectious, and emerging diseases.
Listen to it here: https://bit.ly/3wza2fq
Continue from last post!!
Scientists Develop COVID-19 Lipoprotein Nasal Spray That ...
www.sciencetimes.com › articles › 28144
Nov 10, 2020 · It comprises a lipopeptide, a particle of cholesterol attached to a sequence of amino acids, the protein building blocks. ... Dr. Peter J. Hotez, dean of Baylor College of Medicine's National ...
Scientists Develop COVID-19 Lipoprotein Nasal Spray That Immediately Kills Coronavirus
Tiziana Celine Nov 10, 2020 04:00 PM EST
https://www.sciencetimes.com/articles/28144/20201110/scientists-develop-covid-19-lipoprotein-nasal-spray-that-kills-virus-before-it-infects-cells.htm
FEB 22, 2021 9:06 AM PST
Share
A Nasal Spray That Seems to Prevent the Spread of COVID-19
The spray uses a lipopeptide that's meant to stop the coronavirus from getting into cells. The virus has to use its spike protein to latch on to host cell receptors. When that happens, the virus merges with the host cell membrane and dumps its contents inside, infecting the cell. The lipoprotein stops the viral membrane from fusing with the cell membrane.
https://www.labroots.com/trending/microbiology/19871/nasal-spray-prevent-spread-covid-19
(PDF) Lipopeptide-adjuvanted respiratory syncytial virus ...
www.academia.edu › 10174546 › Lipopeptide_adjuvanted
Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation ... Vaccine, 2010. Toon Stegmann. Download .
https://www.academia.edu/10174546/Lipopeptide_adjuvanted_respiratory_syncytial_virus_virosomes_A_safe_and_immunogenic_non_replicating_vaccine_formulation
Volker Thiel, researcher at the Institute of Virology and Immunology (IVI) and professor at the University of Bern has been carrying out research into coronaviruses in the veterinary field for several years. In the interview he explains. Last interview with Volker Thiel Podcast very interesting.
https://www.blv.admin.ch/blv/en/home/das-blv/forschung/forschungsbericht-2017-2020/erkenntnisse-coronavirus-schwein-sars.html
LY6E impairs coronavirus fusion and confers immune control of ...
www.ncbi.nlm.nih.gov › pmc › articles
Xia S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
LY6E impairs coronavirus fusion and confers immune control of viral disease
Stephanie Pfaender,1,2,3,# Katrina B. Mar,4,# Eleftherios Michailidis,5 Annika Kratzel,1,2,6 Ian N. Boys,4 Philip V`kovski,1,2 Wenchun Fan,4 Jenna N. Kelly,1,2 Dagny Hirt,1,2 Nadine Ebert,1,2 Hanspeter Stalder,1,2 Hannah Kleine-Weber,7,8 Markus Hoffmann,7 H. Heinrich Hoffmann,5 Mohsan Saeed,5,9 Ronald Dijkman,1,2,10,14 Eike Steinmann,3 Mary Wight-Carter,11 Matthew B. McDougal,4 Natasha W. Hanners,12 Stefan Pöhlmann,7,8 Tom Gallagher,13 Daniel Todt,3,14 Gert Zimmer,1,2 Charles M. Rice,5,* John W. Schoggins,4,* and Volker Thiel1,2,*
Author information Copyright and License information Disclaimer
1Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland.
2Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
3Department for Molecular & Medical Virology, Ruhr-Universität Bochum, Germany.
4Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
5Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
6Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
7Deutsches Primatenzentrum GmbH, Leibniz-Institut für Primatenforschung, Göttingen, Germany.
8Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany.
9Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
10Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
11Animal Resource Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
12Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA
13Department of Microbiology and Immunology, Loyola University Chicago, Chicago, USA.
14European Virus Bioinformatics Center (EVBC), Jena, Germany
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916999/
New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential
The Infectious Disease Research Institute
May 10, 2021, 07:00 ET
https://www.prnewswire.com/news-releases/new-adjuvanted-vaccine-candidate-using-idri-formulation-demonstrates-coronavirus-pan-vaccine-potential-301287375.html
Researchers at the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV.
https://debuglies.com/2020/06/22/new-adjuvant-3m-052-helps-induce-long-lasting-immunity-against-hiv/?__cf_chl_jschl_tk__=195aaca3161e6482b8b57561d49306ce6fc0fe68-1624462876-0-AZDq-xpzf7DN_XU80t0AfTN_plaiK2bvn_Vhh73jhHXqsNgVqvzDmFuBTHswqF1xOfMCSP8sFNVqfdtGNUuBWSLaw7-XirwUe6xvK4pbevUxt3cP0feEdlcBVcHf84v-yC4FmhwlTDTGkSKPAfYDiOTJbMA2qpHz5_JUM1kLUcvmStxH3C-185jNPXmNC3yyuH2PQHDLyZWduTGk9AeiCLvLCDhPZizRAKHn0b-nwnGlGY2ezqDJB6rcCwhhv23BxXZZZe9HgCAFsKLupVyUIFiEPcY0p6qz2A_gKNqXhi1a_stnaQFBzDx6VTLq72G5WDg9yEIhMWFiPWQmcmxP2-k7sOdtyJlSGkcoFb_rjgHx3NaxvyOXo24IJ15zDS_9CE7mxtzOjwSJZIB1wxEB_h02_qfKojOWEvLsGdShBKuGw15ezqsZ1q-EHlVBYRoBaPLISbElQD-maCQralQlfIR1xvlttzjksNqiSGTC8AcZ4eIPvamrxaHK1hDyi_mRYF13UbyNlfSkh90IWmSepBTNFc3V6xrOznPHzRIjHb2KQ3QV7qVUdYZRMfJnDnnvUA
Published: 11 June 2021
SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung
Nanda Kishore Routhu, Narayanaiah Cheedarla, Venkata Satish Bollimpelli, Sailaja Gangadhara, Venkata Viswanadh Edara, Lilin Lai, Anusmita Sahoo, Ayalnesh Shiferaw, Tiffany M. Styles, Katharine Floyd, Stephanie Fischinger, Caroline Atyeo, Sally A. Shin, Sanjeev Gumber, Shannon Kirejczyk, Kenneth H. Dinnon III, Pei-Yong Shi, Vineet D. Menachery, Mark Tomai, Christopher B. Fox, Galit Alter, Thomas H. Vanderford, Lisa Gralinski, Mehul S. Suthar & Rama Rao Amara
https://www.nature.com/articles/s41467-021-23942-y
looks like Tobias Balthasar Stähelin is part of Uptown Basel AG Now!!
https://www.moneyhouse.ch/en/company/uptownbasel-ag-18876813071
Fromer Advokatur Und Notariat
https://www.fromer-law.com/advokatur-und-notariat-basel-en.html
819 / 5000
Translation results
Mutation Eardley Holding AG, Basel
Eardley Holding AG
(Eardley Holding SA) (Eardley Holding Ltd)
c / o Dr. Thomas Staehelin
St.Jakobs-Str. 7th
4052 Basel
Eardley Holding AG, in Basel, CHE-100.646.361, Aktiengesellschaft (SHAB No. 218 of
11.11.2019, publ. 1004756501). Peoples registration new or changed: Staehelin,
Dr. Thomas, from Basel, in Vitznau, Chairman of the Board of Directors, with individual signature
[previously: Member of the Board of Directors, with individual signature]; Gähwiler, Felix, from
Kirchberg (SG), in Zumikon, member of the board of directors, with collective signature
two [previously: without a registered function, with a collective signature of two].
Daily register no. 1720 from March 19, 2021
Previous publication in SHAB: No. 218, date: 11/11/2019
Contact point: Commercial Register of the Canton of Basel-Stad
24.03.2021 / Other change (1005132158)
Eardley Holding AG, in Basel, CHE-100.646.361, Aktiengesellschaft (SHAB Nr. 218 vom 11.11.2019, Publ. 1004756501). Eingetragene Personen neu oder mutierend: Staehelin, Dr. Thomas, von Basel, in Vitznau, Präsident des Verwaltungsrates, mit Einzelunterschrift [bisher: Mitglied des Verwaltungsrates, mit Einzelunterschrift]; Gähwiler, Felix, von Kirchberg (SG), in Zumikon, Mitglied des Verwaltungsrates, mit Kollektivunterschrift zu zweien [bisher: ohne eingetragene Funktion, mit Kollektivunterschrift zu zweien].
https://business-monitor.ch/en/companies/18193-eardley-holding-ag
Affiliated Companies with Pictet & Eardley Etude de notaire: SWELL Boards & Style | Civil Protection Office Burg | Dr méd. Olivier Plojoux Médecin généraliste FMH | Providus AG | CATCHUP Communications Ltd.
Other related to Pictet & Eardley Etude de notaire companies: SWELL Boards & Style | Civil Protection Office Burg | Dr méd. Olivier Plojoux Médecin généraliste FMH | Providus AG | CATCHUP Communications Ltd.
Pictet & Eardley Etude de notaire is a company registered in region N\A in Switzerland in 1997. Full company name: Pictet & Eardley Etude de notaire, company of VAT number (USt-ID.Nr., IDE\UID) CHE-932.444.373 VAT, SFI No. CH65426614722, Pub. No. 5141965752. Pictet & Eardley Etude de notaire is located at 4 Rue de Rive, 1204 Genève. P.O. Box: 1211 Genève 3. We offer you a comprehensive range of reports and documents with legal and financial data, facts, analyses and official information from Switzerland. Less 10 people work in this company. Capital - 439,000 CHF. The turnover of the company for the last year amounted to more 342,000,000 CHF and that has negative the creditworthiness. Industry category is notaries. Products created in Pictet & Eardley Etude de notaire were not found.
The main activity of Pictet & Eardley Etude de notaire is pipelines, except natural gas, including 7 other destinations. Information on the owner, director or manager of Pictet & Eardley Etude de notaire is not available. Type of company is Swiss Holding (AG). You can also see reviews of Pictet & Eardley Etude de notaire, open positions and the location of Pictet & Eardley Etude de notaire on the map.
Pictet & Eardley Etude de notaire is a company, that was registered 1997 in N\A region, Switzerland. Full name company: Pictet & Eardley Etude de notaire, company assigned with VAT-IdNr CHE-932.444.373 VAT, Swiss Federal Identification Number CH65426614722 and SOGC 5141965752. The company Pictet & Eardley Etude de notaire is located at the address: Rue de Rive 4, 1204 Genève. P.O. Box: 1211 Genève 3. We bring you a complete range of reports and documents featuring legal and financial data, facts, analysis and official information from Swiss Registry. Less 10 persons work in this company. Capital - 439,000 CHF. The company's sales for last year amounted to More 342,000,000 CHF, and that has Negativ the credit rating. Industry category is Notariate. Products created in Pictet & Eardley Etude de notaire are not found.
The main activity of Pictet & Eardley Etude de notaire is Pipelines, Except Natural Gas, including 7 other destinations. Information about owner, director or manager of Pictet & Eardley Etude de notaire is not available. Type of company is Swiss Holding (AG). You also can view reviews of Pictet & Eardley Etude de notaire, open positions, location of Pictet & Eardley Etude de notaire on the map.
https://ydo.ch/companies/286701/pictet-eardley-etude-de-notaire/
Researchers create the most comprehensive atlas of human ...
australianonlinenews.com.au › 2021/06/18
Jun 18, 2021 · Together with Baylor College of Medicine and the world's leading sequencing company, Illumina, researchers at Ghent University...
Together with Baylor College of Medicine and the world's leading sequencing company, Illumina, researchers at Ghent University have built one of the most comprehensive catalogs of the human transcriptome ever. By cleverly combining complementary sequencing techniques they have deepened our understanding of the function of known RNA molecules and discovered thousands of new RNAs. A better understanding of our transcriptome is essential to better understand disease processes and uncover novel genes that may serve as therapeutic targets or biomarkers.
https://australianonlinenews.com.au/2021/06/18/researchers-create-the-most-comprehensive-atlas-of-human-transcriptome-news-medical-net/
https://www.news-medical.net/news/20210618/Researchers-create-the-most-comprehensive-atlas-of-human-transcriptome.aspx
2020 Insights into the Cancer Vaccines Market - Pipeline Analysis Report - ResearchAndMarkets.com
July 22, 2020 08:04 AM Eastern Daylight Time
DUBLIN--(BUSINESS WIRE)--The "Cancer Vaccines Market, Pipeline Analysis Report 2020" report has been added to Research And Markets. com's offering
Cancer Vaccines Market, Pipeline Analysis Report 2020
11. Emerging Players Analysis
11.16 ViciniVax
11.10 IO Biotech
https://www.businesswire.com/news/home/20200722005470/en/2020-Insights-Cancer-Vaccines-Market---Pipeline
RONALD KEMPERS
President, Chief Executive Officer, Chief Financial Officer, Chief Compliance Officer
President, Chief Executive Officer & Chief Financial Officer
Chief Operating Officer
2009 - Current
Director
Prior
JAN C. WILSCHUT
Mymetics Corp.
Member, Scientific Advisory Board
Current
https://relationshipscience.com/connections/ronald-kempers-4212539
mymetics corporation – The Cancer Consortium
www.thecancerconsortium.org › tag › mymetics-corporation
Jun 05, 2021 · Members of the Global Cancer Consortium believe that progress occurs through collaboration which can occur through improved information. This news site aggregates information and profiles of the member companies and organizations. Its Cancer Progress Report reaches thousands of investors and industry professionals.
mymetics corporation – The Cancer Consortium
www.thecancerconsortium.org › tag › mymetics-corporation
Jun 05, 2021 · The Cancer Consortium was formed by the Altru Cancer Project to offer one place to learn about the most promising developments, technologies and companies focused on Cancer.
CAN NOT PULL THESE UP!!!!!!!
TRANSVAC2 thus far, projects and numbers | TRANSVAC
www.transvac.org › vaccine-projects-statistics
More Trans-National Access in TRANSVAC2, so far...
TNA1709-01 (Call 01)
Pre-clinical development of a multi-stage malaria virosome based vaccine adjuvanted with a membrane anchored TLR7/8 agonist for optimal immunogenicity in infants and children.
TEMUSTMAV
Mymetics SA BV
The Netherlands
Human vaccine
Target:
Malaria
The overall objective was to manufacture the CyRPA antigen, followed by its incorporation into a novel multi-stage malaria vaccine formulation against Plasmodium falciparum (Pf), based on the influenza virosomes acting as synthetic lipid-based particle carriers. This vaccine contains two virosomes, each with two surface antigens: one with the highly conserved antigens CyRPA & RH5 as recombinant proteins and one virosome with AMA and CSP peptidomimotopes. These virosomes contain the TLR7/8 adjuvant suitable for infants, children and adults. Adjuvants and antigens are physically bound to the same virosome for improving the vaccine safety and tolerance profile. Mice and rabbit immunized with the two combined virosomes developed good antibody levels toward each antigen, capable of binding to the parasite and strongly reducing its infectivity in laboratory tests. Human vaccinated with this malaria vaccine candidate should develop anti-parasite antibodies preventing/controlling red blood cell infection, greatly alleviating symptoms and reducing risk of severe malaria.
https://www.transvac.org/vaccine-projects-statistics
Could a Nasal Spray of Designer Antibodies Help to Beat COVID-19?
Posted on June 15th, 2021 by Dr. Francis Collins
https://directorsblog.nih.gov/2021/06/15/could-a-nasal-spray-of-designer-antibodies-help-to-beat-covid-19/
https://www.fox35orlando.com/news/nasal-spray-could-potentially-treat-covid-19-nih-says
Nasal Vaccines for COVID-19
Safety is another consideration. The majority of mucosal vaccines licensed in the U.S. are delivered via the oral route. Perhaps because of closer proximity to the brain, vaccine regulators appear to have shied away from the intranasal route. For example, Berna Biotech’s inactivated intranasal influenza vaccine was discontinued in Switzerland after it was found to be associated with increased risk of Bell’s Palsy.
Still, because oral vaccination tends to produce an antibody response that is not so strong in the respiratory tract, Russell contends that intranasal immunization “makes the most sense” for a respiratory pathogen like SARS-CoV-2.
“If similar resources can be made available for the accelerated development of intranasal vaccines, as have been deployed for the existing vaccines, my guess is that we might see some of them becoming available within about a year,” he said.
Why would they mention Berna Biotech in this Article??
https://www.nanovaccine.iastate.edu/researchers/richard-kennedy-phd/nasal-vaccines-for-covid-19/
Intranasal vaccines aim to stop COVID-19 where it starts
cen.acs.org › pharmaceuticals › vaccines
Jun 06, 2021 · An intranasal flu vaccine made by Berna Biotech and approved in Switzerland in 1997 was linked to rare cases of Bell’s palsy—a usually temporary facial paralysis—after it was commercialized.
https://cen.acs.org/pharmaceuticals/vaccines/Intranasal-nose-vaccines-stop-COVID/99/i21